Twist Bioscience Corporation
Foreign stocks · NASDAQ · Healthcare · Biotechnology
Makes synthetic DNA for synthetic biology research, drug development and DNA data storage. Most revenue comes from selling custom DNA to labs and biotech companies
Investors in Thailand can buy TWST through 13 mutual funds open to retail investors. Most of them (13 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds TWST.
| Fund | TWST weight | How it invests | 1-year return |
|---|---|---|---|
 ES-GENOMEEastspring Genomic Revolution Fund | 10.83% | Via several master funds (ARK Genomic Revolution UCITS, ARK Genomic Revolution, iShares Genomics Immunology and Healthcare) | +56.72% |
 SCBGENOME(A)SCB Genomic Revolution | 10.03% | Via several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare) | +61.33% |
 TGENOMETISCO Genomic Revolution Fund | 8.90% | Via several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare, ISHARES BIOTECHNOLOGY) | +54.22% |
 ONE-DISC-ASSFONE DISCOVERY FUND | 5.92% | Via Baillie Gifford Worldwide Discovery Fund | −1.98% |
| ONE-DISCRMF-AONE DISCOVERY RETIREMENT MUTUAL FUND | 5.88% | Via Baillie Gifford Worldwide Discovery Fund | −2.08% |
 LHINNO-ALH INNOVATION FUND | 4.60% | Via several master funds | −12.68% |
| ES-INTERNETEastspring Next Generation Internet Fund | 3.24% | Via several master funds (ARK Innovation UCITS, ARK NEXT GENERATION INTERNET ETF, ALPS O'Shares Global Internet Giants) | −14.52% |
 ASP-IHEALTHAsset Plus Innovative Healthcare Fund | 2.69% | Via several master funds (JHHBIU2 LX, ARKG US) | +20.72% |
 BCAP-XHEALTHBCAP NEXT GEN Health Fund | 1.92% | Via several master funds | +17.62% |
| ASP-USSMALL-AAsset Plus U.S. Small Cap Focus Fund | 1.63% | Via Driehaus US Small Cap Equity Fund | −9.62% |
Yearly average over the last 4 years · Latest annual sales 377.0M USD
For every 100 dollars of sales, about −21 dollars is left as net profit
Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits
Now 30.4% below its 1-year high
| Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenue | 132.0M USD | 204.0M USD | 245.0M USD | 313.0M USD | 377.0M USD |
| Gross profit | 52.0M USD | 84.0M USD | 90.0M USD | 133.0M USD | 191.0M USD |
| Operating profit | −153.0M USD | −235.0M USD | −217.0M USD | −221.0M USD | −136.0M USD |
| Net profit | −152.0M USD | −218.0M USD | −205.0M USD | −209.0M USD | −78.0M USD |
| EPS (diluted) | −3.15 | −4.04 | −3.60 | −3.60 | −1.30 |
| Gross margin | 39.4% | 41.2% | 36.7% | 42.5% | 50.7% |
| Operating margin | −115.9% | −115.2% | −88.6% | −70.6% | −36.1% |
| Net margin | −115.2% | −106.9% | −83.7% | −66.8% | −20.7% |
| Operating cash flow | −112.0M USD | −124.0M USD | −142.0M USD | −64.0M USD | −48.0M USD |
| Free cash flow | −139.0M USD | −226.0M USD | −170.0M USD | −69.0M USD | −76.0M USD |
| Total assets | 702.0M USD | 961.0M USD | 776.0M USD | 614.0M USD | 642.0M USD |
| Total liabilities | 121.0M USD | 172.0M USD | 153.0M USD | 142.0M USD | 169.0M USD |
| Shareholders' equity | 581.0M USD | 789.0M USD | 623.0M USD | 472.0M USD | 473.0M USD |
| Period | SMA | EMA | Price vs line |
|---|---|---|---|
| 10 days | 149.21 | 147.83 | Below |
| 20 days | 148.21 | 150.62 | Below |
| 50 days | 152.59 | 146.60 | Below |
| 100 days | 127.70 | 129.10 | Above |
| 200 days | 90.45 | 102.66 | Above |
| Indicator | Value | Signal |
|---|---|---|
| RSI(14) | 46.43 | Down |
| MACD(12,26) | −2.56 | Down |
| ADX(14) | 19.61 | Neutral |
| ATR(14) % of price | 6.45 | Neutral |
The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position
EASTSPRING2SCBAM2ONEAM2ASSETFUND2BBLAM2TISCOASSET1LHFUND1
DAOLINV1| Fund | TWST weight | Master fund | 1-year return | TER |
|---|---|---|---|---|
| ES-GENOME | 10.83% | several master funds (ARK Genomic Revolution UCITS, ARK Genomic Revolution, iShares Genomics Immunology and Healthcare) | +56.72% | 1.25% |
| SCBGENOME(A) | 10.03% | several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare) | +61.33% | 0.62% |
| TGENOME | 8.90% | several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare, ISHARES BIOTECHNOLOGY) | +54.22% | 1.28% |
| ONE-DISC-ASSF | 5.92% | Baillie Gifford Worldwide Discovery Fund | −1.98% | 1.80% |
| ONE-DISCRMF-A | 5.88% | Baillie Gifford Worldwide Discovery Fund | −2.08% | 1.90% |
| LHINNO-A | 4.60% | several master funds | −12.68% | 1.58% |
| ES-INTERNET | 3.24% | several master funds (ARK Innovation UCITS, ARK NEXT GENERATION INTERNET ETF, ALPS O'Shares Global Internet Giants) | −14.52% | 1.25% |
| ASP-IHEALTH | 2.69% | several master funds (JHHBIU2 LX, ARKG US) | +20.72% | 2.83% |
| BCAP-XHEALTH | 1.92% | several master funds | +17.62% | 1.23% |
| ASP-USSMALL-A | 1.63% | Driehaus US Small Cap Equity Fund | −9.62% | 2.48% |
| DAOL-USSMALL | 1.29% | FYC | N/A | 1.96% |
| SCBRS2000(A) | 0.43% | IWM | +10.46% | 1.17% |
| B-US2000P | 0.42% | IWM | +18.60% | 0.89% |
| Master fund | Thai funds using this route | Master fund's TWST weight |
|---|---|---|
| Baillie Gifford Worldwide Discovery Fund | 2 | 5.92% |
| several master funds | 2 | 4.60% |
| iShares Russell 2000 ETF | 2 | 0.43% |
| several master funds (ARK Genomic Revolution UCITS, ARK Genomic Revolution, iShares Genomics Immunology and Healthcare) | 1 | 10.83% |
| several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare) | 1 | 10.03% |
| several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare, ISHARES BIOTECHNOLOGY) | 1 | 8.90% |
| several master funds (ARK Innovation UCITS, ARK NEXT GENERATION INTERNET ETF, ALPS O'Shares Global Internet Giants) | 1 | 3.24% |
| several master funds (JHHBIU2 LX, ARKG US) | 1 | 2.69% |
| Driehaus US Small Cap Equity Fund | 1 | 1.63% |
| First Trust Small Cap Growth AlphaDEX® Fund | 1 | 1.29% |
